Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities

Table 2 Comparison of treatment modalities between 5-year survival group and 10-year survival group for hepatocellular carcinoma

Treatment modalities by tumor type	5-yr survival group	10-yr survival group	P value between groups	P value between overall groups
No. of treatment modalities				0.092
Surgery alone	609	235
TACE alone	214	80
Surgery + TACE	458	125
TACE + RFA	85	28
Surgery + TACE + RFA	150	52
Tumor size ≤ 5 cm (maximum diameter)				0.097
Surgery alone	244 (3.53 ± 1.03)	100 (3.48 ± 1.06)	0.217
TACE alone	92 (2.59 ± 1.16)	38 (3.58 ± 1.16)	0.087
Surgery + TACE	133 (3.90 ± 1.02)	43 (3.47 ± 1.03)	0.192
TACE + RFA	72 (3.10 ± 1.16)	21 (2.93 ± 1.10)	0.824
Surgery + TACE + RFA	82 (3.88 ± 0.91)	26 (3.42 ± 0.98)	0.314
Tumor size > 5 cm (maximum diameter)				0.106
Surgery alone	365 (8.16 ± 2.27)	135 (8.532 ± 2.71)	0.130
TACE alone	122 (9.31 ± 2.94)	42 (9.36 ± 2.26)	0.925
Surgery + TACE	325 (9.59 ± 3.16)	82 (9.09 ± 2.50)	0.624
TACE + RFA	13 (11.68 ± 3.74)	7 (10.47 ± 5.59)	0.548
Surgery + TACE + RFA	68 (7.19 ± 3.02)	26 (10.65 ± 4.63)	0.131
Uninodular HCC				0.039
Surgery alone	531	223
TACE alone	178	75
Surgery + TACE	382	113
TACE + RFA	57	24
Surgery + TACE + RFA	100	50
Multinodular HCC
Surgery alone	78	12
TACE alone	36	5
Surgery + TACE	76	12
TACE + RFA	28	4		0.445
Surgery + TACE + RFA	50	2
AFP > 400 ng/mL (AFP value)				0.289
Surgery alone	280 (16053.09 ± 27804.11)	102 (18092.07 ± 26818.62)	0.450
TACE alone	66 (15876.11 ± 30406.63)	28 (10984.83 ± 18402.28)	0.270
Surgery + TACE	188 (21164.79 ± 31964.15)	47 (25114.26 ± 31807.02)	0.385
TACE + RFA	32 (742.50 ± 0.00)	12 (22597.20 ± 28745.64)	0.667
Surgery + TACE + RFA	56 (1884.33 ± 953.25)	19 (8789.88 ± 21862.41)	0.091
AFP < 400 ng/mL (AFP value)				0.065
Surgery alone	329 (45.50 ± 71.08)	133 (56.35 ± 91.86)	0.853
TACE alone	148 (38.60 ± 71.56)	52 (38.09 ± 48.30)	0.355
Surgery + TACE	270 (66.35 ± 98.86)	78 (43.02 ± 74.45)	0.738
TACE + RFA	69 (133.34 ± 145.64)	16 (44.81 ± 43.02)	0.579
Surgery + TACE + RFA	94 (96.06 ± 138.35)	33 (15.43 ± 8.21)	0.064

AFP: α-fetoprotein; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation; HCC: Hepatocellular carcinoma.